Mobile Enhanced Prevention Support
BehavioralAccess to the newly developed GeoPassport App, incentives for accessing identified services, and a trained Peer Mentor.
Other names: MEPS
NCT Number: NCT04036396
This study will provide HIV prevention and related support services to men who have sex with men and transgender women who have substance use disorders and are either leaving jail or recently released from jail. The researchers will compare the utilization of HIV prevention and other support services between individuals who receive routine case management provided following enrollment to those who have access to GeoPassport, a global position service (GPS)-based mobile app, incentives, and peer mentor support.
Looking for future studies?
Notify Me18 year–49 year
Male
Interventional
Not applicable
God's Property, Los Angeles, California, United States
The investigators will enroll 200 people in jail or within 12 months post-release from incarceration. During the trial, half of participants will be randomized into a control group that will receive usual care consistent with the setting in which they live, along with referrals customized to their needs and preferences to share with a case manager. They will be compared to the other half of participants randomized to the intervention group that, in addition to receiving customized referral sources, will also receive the GeoPassport App, incentives, and the support of a trained Peer Mentor for six months. The GeoPassport App will provide participants with tools for tracking goals and progress toward meeting them, assistance in locating services, appointment and medication reminders, opportunities to provide feedback on service providers, and built-in tracking and distribution of rewards (incentives) for service utilization. GeoPassport will assist Peer Mentors in monitoring participants' service utilization. The Peer Mentors will provide encouragement, role modeling, accompaniment to appointments, and assistance with goal setting, problem-solving, and reducing logistical and psychosocial barriers to service engagement. The intervention can be delivered in person or remotely in order to comply with necessary social distancing during the COVID-19 pandemic. Participants in both groups will be followed to assess whether those offered the intervention are more likely to meet the specific prevention targets described in the Specific Aims. The intervention lasts 6 months from the start of participation. Participants are interviewed at 3, 6, and 9 months from the same point as the intervention.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Access to the newly developed GeoPassport App, incentives for accessing identified services, and a trained Peer Mentor.
Other names: MEPS
Participants in the control arm will continue to receive services they would normally receive consistent with the setting in which they were recruited. This includes substance use treatment in jail, substance use treatment at a residential recovery facility, and/or supportive housing services. The study will provide referrals customized to their needs and preferences.
Time frame: 9 months
Defined as the participant identifying and completing an appointment with a primary care provider who is willing and able to prescribe HIV pre-exposure prophylaxis.
Time frame: 9 months
Defined as the participant obtaining a prescription for PrEP, providing documentation, reporting taking the medication
Time frame: 3, 6, or 9 months
Defined as the participant self-reporting taking prescribed PrEP at least 4 days per week at first instance of reporting taking PrEP
Time frame: 9 months
The outcomes is defined by self-reported PrEP use for 3 or more months
Time frame: 3, 6, and 9 months
Defined as the participant self-reporting having obtained HIV testing within 3 months of the follow-up
Time frame: 6 and 9 months
Defined by the participant self-reporting having obtained testing for these sexually transmitted diseases (STDs) within the 6 months prior to a follow-up over the 9 month follow-up period
Time frame: 9 months
Defined by the participant self-reporting having obtained at least one test for Hepatitis C
Time frame: 3 months
Defined by the participant self-report of completing SUD appointments within the 3 months following enrollment
Time frame: 9 months
Defined by the participant self-reporting remaining engaged in treatment (i.e., continuing to attend meetings, counseling or other treatment activities) in the 3 months prior to the final follow-up interview.
Time frame: 3, 6, or 9 months
Self-report of whether or not participants received follow-up care and treatment for HIV or hepatitis C infections diagnosed during study follow-up (n=200)
Time frame: 9 months
Measure the comparative effectiveness of each intervention arm on reducing recidivism (n=200), quantified as the number of respondents who are reincarcerated.
Time frame: 9 months
Measure the comparative effectiveness of the intervention reducing recidivism (n=200), quantified as total number of reincarcerations over the study period among those who recidivate.
University of California, Los Angeles
Other
Acronym: MEPS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05472051
Actinomycetales Infections, Bacterial Infections
Bamako, Niamakoro, Sièbougouni, Rue 173, Porte 146, Mali
View Trial DetailsNCT04134767
Blood-Borne Infections, Chemically-Induced Disorders
Lexington, Kentucky, United States
View Trial DetailsNCT05307991
Bacterial Infections, Bacterial Infections and Mycoses
Lilongwe, Malawi
View Trial DetailsNCT03369249
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Brooklyn, New York, United States
View Trial Details